ArticlemAbs2025
What does AlphaFold3 learn about antibody and nanobody docking, and what remains unsolved?
Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Article
- Article
- Article
- Article
- Antibody-drug conjugate engineering: from design to efficacy and safety.Signal transduction and targeted therapy · 2026Review
- Combining AI Structure Prediction and Integrative Modeling for Nanobody-Antigen Complexes.Journal of chemical information and modeling · 2026Article
- ProteinDock: A physics-informed layer to improve protein-protein docking reliability.bioRxiv : the preprint server for biology · 2026Article
- Benchmarking AlphaFold and related deep learning approaches for modeling antibody and TCR antigen recognition.bioRxiv : the preprint server for biology · 2026Article
- AbTune: layer-wise selective fine-tuning of protein language models for antibodies.Briefings in bioinformatics · 2026Article
- Efficient generation of epitope-targeted antibodies with Germinal.Nature biotechnology · 2026Article
- Adaptive Disorder as the Hallmark of Nanobodies Antigen-Binding Loops.Journal of chemical information and modeling · 2026Article
- Benchmarking TCR-pMHC structure prediction: a unified evaluation and CDR3-based functional insights.Briefings in bioinformatics · 2026Article
- Repertoire-scale antibody structural prediction informs therapeutic design.Science advances · 2026Article
- The adaptive immune receptors in a big data world.ImmunoHorizons · 2026Review
- Confidence scoring for deep learning-predicted antibody-antigen complexes: AntiConf as a precision-driven metric.Briefings in bioinformatics · 2026Article
- Disulphide and sequence-encoded conformational priors guide nanobody structure prediction.bioRxiv : the preprint server for biology · 2026Article
- Ab-SELDON: Leveraging Diversity Data for an Efficient Automated Computational Pipeline for Antibody Design.Journal of chemical information and modeling · 2026Article
- Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors.Pharmacology research & perspectives · 2026Review
- Paraplume: A fast and accurate antibody paratope prediction method provides insights into repertoire-scale binding dynamics.PLoS computational biology · 2026Article
- Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026Review
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
Antibody therapeutic development is a major focus in healthcare. To accelerate drug development, significant efforts have been directed toward the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.